Alcon to Acquire Ivantis for ~$475M
Shots:
- Ivantis to receive $475M up front along with additional payments upon achievement of regulatory & commercial milestones. The transaction is expected to close in Q122
- The acquisition expands Alcons surgical portfolio & uses the commercial execution expertise across cataract, refractive, retina & glaucoma. Hydrus Microstent is approved for use in conjunction with cataract surgery in the US & for standalone use or in conjunction with cataract surgery in the UK, Canada, Australia, Singapore & Germany
- The HORIZON study of Hydrus Microstent showed 65% remained medication-free @5yrs. post-implant, 60% reduction in risk of invasive secondary glaucoma surgeries over cataract surgery alone
Ref: Alcon | Image: Alcon
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com